Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression